Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BARR SALES DROP 42% FOR YEAR AFTER FDA RULING; ZENECA CASE YIELDS $7.9 MIL. PROFIT

Executive Summary

Barr Labs sales for the year ended June 30 plunged 42% as a result of the suspension of much of the generic drug manufacturer's product line following litigation with FDA. Barr reported sales of $58 mil. for the year, compared to $100.8 mil. for fiscal 1992. On Feb. 4, Newark federal court Judge Alfred Wolin ordered Barr to cease distribution of 24 products following a court case between Barr and FDA over manufacturing compliance issues. Despite the regulatory setback, Barr posted a $7.9 mil. profit for the year on the strength of $21 mil. in payments from Zeneca as part of a settlement of patent litigation relating to Nolvadex. Without the payments, Barr said, it would have lost $5 mil. for the year. Barr lost $1.9 mil. in fiscal 1992. Barr will begin marketing a generic tamoxifen supplied by Zeneca Nov. 1 as part of the March settlement. The firm has reintroduced eight of the suspended products and "is optimistic that it will continue to reintroduce other suspended products." Genetics Institute posted product sales of $25.9 mil. for the nine months ended Aug. 31, the company reported. Third quarter product sales were $9.1 mil. The figures represent sales of Factor VIII concentrate to Baxter.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS023387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel